Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4087750 | 0.99 | PTGDR2 (0.54) | PTGDR2KDM4EPOLBMEN1KMT2A | |
| SCHEMBL347924 | 0.85 | AR (0.58) | PTGDR2KDM4EPOLBMEN1KMT2A | |
| SCHEMBL347552 | 0.78 | PTGDR2 (0.62) | PTGDR2KDM4EPOLBMEN1KMT2A | |
| SCHEMBL347670 | 0.78 | GAA (0.55) | PTGDR2KDM4EPOLBMEN1KMT2A | |
| SCHEMBL4497493 | 0.72 | PTGDR2 (1.00) | PTGDR2KDM4EPOLBKMT2AALDH1A1 | |
| SCHEMBL3768315 | 0.72 | AR (0.67) | RAB9ANPC1ALDH1A1HPGDAR | |
| SCHEMBL10220617 | 0.72 | ALDH1A1 (0.54) | MEN1KMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL10220600 | 0.72 | RAB9A (0.72) | POLBMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL348219 | 0.72 | AR (0.48) | PTGDR2KDM4EPOLBMEN1KMT2A | |
| SCHEMBL347529 | 0.70 | AR (0.49) | KDM4EMEN1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160199386-A1 | METHODS OF TREATING THYROID EYE DISEASE | UNIVERSITY OF ROCHESTER (US) | 2016-07-14 | — | — | US | claimed |
| US-20120015001-A1 | METHODS OF TREATING THYROID EYE DISEASE | UNIVERSITY OF ROCHESTER (US) | 2012-01-19 | — | — | US | claimed |
| US-9750749-B2 | Methods of treating thyroid eye disease | UNIVERSITY OF ROCHESTER (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160199386-A1 | METHODS OF TREATING THYROID EYE DISEASE | UNIVERSITY OF ROCHESTER (US) | 2016-07-14 | — | — | US | disclosed |
| US-9320723-B2 | Methods of treating thyroid eye disease | UNIVERSITY OF ROCHESTER (US) | 2016-04-26 | — | — | US | disclosed |
| US-20120015001-A1 | METHODS OF TREATING THYROID EYE DISEASE | UNIVERSITY OF ROCHESTER (US) | 2012-01-19 | — | — | US | disclosed |
| US-20090221604-A1 | Thiazole Compounds and Their Use as PGD2 Antagonists | ARGENTA DISCOVERY LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221604-A1 | Thiazole Compounds and Their Use as PGD2 Antagonists | ARGENTA DISCOVERY LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221604-A1 | Thiazole Compounds and Their Use as PGD2 Antagonists | ARGENTA DISCOVERY LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| EP-1922312-A1 | THIAZOLE COMPOUNDS AND THEIR USE AS PGD2 ANTAGONISTS | Argenta Discovery Limited (GB) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007028999-A1 | THIAZOLE COMPOUNDS AND THEIR USE AS PGD2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007028999-A1 | THIAZOLE COMPOUNDS AND THEIR USE AS PGD2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221604-A1 | Thiazole Compounds and Their Use as PGD2 Antagonists | PTGDR2, PTGDR, PTGER2 | PTGDR2 1/4885KDM4E 4408/4885POLB 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.